
Budget 2023 may offer Research Linked Incentive scheme for Indian pharma
RLI is expected to provide an extra financial cushion, in addition to the existing R&D sops available to pharmaceutical and biotech companies operating in India.
RLI is expected to provide an extra financial cushion, in addition to the existing R&D sops available to pharmaceutical and biotech companies operating in India.
A majority of pharma stocks reported double digit negative returns, while the overall market (BSE Sensex) delivered a 9% plus return.
The domestic formulations market is expected to grow 7-9% this fiscal.
2022 will be the year of incubation for technological advancements that will shape the personalisation of healthcare and therapies for the next five decades.
In the coming year, the pharma industry will continue to reimagine itself while driving growth and boosting value.